Our flagship innovation, the Victoria Graft System (VGS), is the first autologous graft system designed specifically for prolapse surgery. It uses a woman’s own blood to create two soft tissue grafts during the procedure, supporting structural repair while accelerating healing.
Many women feel limited by today’s prolapse treatment options. Traditional native tissue repairs can have high recurrence rates, while synthetic mesh has led to complications and regulatory withdrawals.
SmartFem addresses this with a biologically personalised, regenerative approach that works in partnership with the body.
Made from the patient’s own blood, the graft provides temporary mechanical support while the body repairs itself.
Promotes resorption and integration over time, without leaving permanent foreign materials in the body.
Compatible with anterior and posterior repairs. It works alongside native tissue repairs without requiring additional surgical infrastructure.
Compatible with anterior and posterior repairs. It works alongside native tissue repairs without requiring additional surgical infrastructure. The system is designed to be processed during surgery, using familiar tools and steps that fit into theatre routines.
Pelvic organ prolapse is a common condition, with studies suggesting that 30-50% of women may experience it at some point in their lives. Risk factors include childbirth, obesity, menopause and ageing.
A significant proportion of women will require surgical repair to correct their prolapse. SmartFem offers a new, regenerative approach to:
Backed by 400+ procedures based on our preliminary findings with zero reported adverse events, SmartFem has been adopted in public and private hospitals across Australia and developed under clinical-grade manufacturing standards.
